| Large-scale applications of transition metal-catalyzed couplings for the synthesis of pharmaceuticals | Chemical Reviews | 2011 | 1.2K |
| Impact of high-throughput screening in biomedical research | Nature Reviews Drug Discovery | 2011 | 768 |
| Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1 | Value in Health | 2011 | 673 |
| Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction | BJU International | 2011 | 596 |
| American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials | Arthritis and Rheumatism | 2011 | 520 |
| Neuropsychiatric symptoms in Alzheimer's disease | Alzheimer's and Dementia | 2011 | 508 |
| Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2 | Value in Health | 2011 | 478 |
| CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib | Journal of Clinical Oncology | 2011 | 450 |
| Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup | Alzheimer's and Dementia | 2011 | 364 |
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Journal of Clinical Oncology | 2011 | 364 |
| Managing the challenge of chemically reactive metabolites in drug development | Nature Reviews Drug Discovery | 2011 | 348 |
| Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib | Blood | 2011 | 345 |
| Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions | Journal of the American Academy of Dermatology | 2011 | 343 |
| Key Green Engineering Research Areas for Sustainable Manufacturing: A Perspective from Pharmaceutical and Fine Chemicals Manufacturers | Organic Process Research and Development | 2011 | 308 |
| Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year | Arthritis and Rheumatism | 2011 | 307 |
| Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis | Journal of Investigative Dermatology | 2011 | 276 |
| On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds | Nature Chemical Biology | 2011 | 264 |
| Medication adherence: a call for action | American Heart Journal | 2011 | 263 |
| Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? | Journal of the American College of Cardiology | 2011 | 250 |
| Impact of product-related factors on immunogenicity of biotherapeutics | Journal of Pharmaceutical Sciences | 2011 | 248 |
| How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? | British Journal of Pharmacology | 2011 | 247 |
| Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin | Clinical Cancer Research | 2011 | 229 |
| Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate | Arthritis Care and Research | 2011 | 221 |
| Development of a new permeability assay using low-efflux MDCKII cells | Journal of Pharmaceutical Sciences | 2011 | 220 |
| Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial | Arthritis and Rheumatism | 2011 | 218 |
